Avalo Therapeutics (AVTX) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company focused on immune dysregulation, with a lead asset AVTX-009 (anti-IL-1β monoclonal antibody) targeting inflammatory diseases.

• Pipeline includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), with strategic reviews ongoing for some programs.

• Recent acquisition of AlmataBio, Inc. added AVTX-009 to the pipeline through a stock-for-stock transaction and milestone-based payments.

• Operates under exclusive global licenses for key assets from Eli Lilly, Kyowa Kirin, and Sanford Burnham Prebys.

Financial performance and metrics

• Closed a private placement in March 2024 for up to $185 million in gross proceeds, with an initial $115.6 million upfront; net proceeds were approximately $108.1 million after transaction costs.

• Cash payment of $7.5 million made to former AlmataBio stockholders in April 2024 as part of the acquisition.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of securities by selling stockholders; may receive up to $69.4 million if all warrants are exercised for cash, allocated to working capital.

• All registration and prospectus costs are borne by the company, while selling stockholders pay brokerage fees and commissions.